Cell line · CVCL_5546
Papers30
2 more articles give this line's RRID in its Methods without naming the line nearby, so they are not listed.
1 to 20 of 30
Download this page as JSON| Paper | Journal | Year | How we know | Retracted | Source |
|---|---|---|---|---|---|
| Hsa_Circ_0000615-Encoded 250-Amino Acid Polypeptide Suppresses Epithelial Ovarian Cancer Progression via Promoting HMGB1 Nuclear Accumulation. | Oncol Res | 2026 | Its Methods give the RRID and name the line | PubMed | |
| In silico design of CLDN4-directed peptide-loaded nanobubbles for ultrasound-assisted delivery, photothermal therapy, immune activation, and multimodal imaging in ovarian cancer. | J Nanobiotechnology | 2026 | Its Methods give the RRID and name the line | PubMed | |
| Overexpression of SLC44A4 suppresses ferroptosis and reduces lipid peroxidation via noncanonical NF-κB signaling in a NIK-dependent manner. | Ann Med | 2026 | Its Methods give the RRID and name the line | PubMed | |
| Large-Scale Quantitative Morphometry of Platelet α-Granules via SIM Super-Resolution Microscopy for Cancer Liquid Biopsy. | Adv Sci (Weinh) | 2026 | Its Methods give the RRID and name the line | PubMed | |
| The long noncoding RNA AC093895.1 promotes ovarian cancer formation and metastasis through a positive feedback network dependent on the transcription factor SOX4. | Cell Death Dis | 2026 | Its Methods give the RRID and name the line | PubMed | |
| IPO9 Promotes Ovarian Cancer Progression by Suppressing HMOX1-Dependent Ferroptosis. | Hum Mutat | 2026 | Its Methods give the RRID and name the line | PubMed | |
| M6A modification mediates CACNA1A stability to drive the progression of ovarian cancer by inhibiting ferroptosis. | J Ovarian Res | 2025 | Its Methods give the RRID and name the line | PubMed | |
| HGF knockdown suppresses ovarian cancer malignancy: insights from a transient receptor potential-related gene model. | Eur J Med Res | 2025 | Its Methods give the RRID and name the line | PubMed | |
| Prediction of Immunotherapy Response and Prognostic Outcomes for Patients With Ovarian Cancer Using PANoptosis-Related Genes. | Hum Mutat | 2025 | Its Methods give the RRID and name the line | PubMed | |
| 3β-Hydroxysterol Δ24-Reductase Promotes Ovarian Cancer Progression by Activating the TGF-β1/Smad2/3 Signaling Pathway. | Oncol Res | 2025 | Its Methods give the RRID and name the line | PubMed | |
| Serum-derived exomiR-188-3p is a promising novel biomarker for early-stage ovarian cancer. | Open Med (Wars) | 2025 | Its Methods give the RRID and name the line | PubMed | |
| SLC4A11 is a targetable marker correlated with therapeutic responses in ovarian cancer. | J Ovarian Res | 2025 | Its Methods give the RRID and name the line | PubMed | |
| METTL2B m3C RNA transferase: oncogenic role in ovarian cancer progression via regulation of the mTOR/AKT pathway and its link to the tumor immune microenvironment. | BMC Cancer | 2024 | Its Methods give the RRID and name the line | PubMed | |
| SLC45A4 is involved in malignant progression of ovarian cancer through glycolytic metabolic reprogramming. | Sci Rep | 2024 | Its Methods give the RRID and name the line | PubMed | |
| Identification and validation of immunity- and disulfidptosis-related genes signature for predicting prognosis in ovarian cancer. | Heliyon | 2024 | Its Methods give the RRID and name the line | PubMed | |
| Identification of the biological functions and chemo-therapeutic responses of ITGB superfamily in ovarian cancer. | Discov Oncol | 2024 | Its Methods give the RRID and name the line | PubMed | |
| RPL35A drives ovarian cancer progression by promoting the binding of YY1 to CTCF promoter. | J Cell Mol Med | 2024 | Its Methods give the RRID and name the line | PubMed | |
| m6A methylation-mediated regulation of LncRNA MEG3 suppresses ovarian cancer progression through miR-885-5p and the VASH1 pathway. | J Transl Med | 2024 | Its Methods give the RRID and name the line | PubMed | |
| Revealing the inhibitory effect of VASH1 on ovarian cancer from multiple perspectives. | Cancer Biol Ther | 2023 | Its Methods give the RRID and name the line | PubMed | |
| Long non-coding RNA SLC25A21-AS1 inhibits the development of epithelial ovarian cancer by specifically inducing PTBP3 degradation. | Biomark Res | 2023 | Its Methods give the RRID and name the line | PubMed |
cell-lines-2026-11-14-0.1.0
Sources 4
- CellosaurusCC BY 4.0, with credit to Cellosaurus (SIB)
- PubMed Central's articlesTitles shown only for CC0, CC BY and public domain articles
- NLM's PMC Article DatasetsCourtesy of NLM, which does not endorse this database
- PubMedNLM's terms
Each source's terms
- CellosaurusCC BY 4.0. Cellosaurus's README: "we have chosen to apply the Creative Commons Attribution 4.0 International (CC BY 4.0) license to Cellosaurus (https://creativecommons.org/licenses/by/4.0/). This means that you are free to copy and redistribute Cellosaurus in any medium or format. You can remix, transform, and build upon Cellosaurus for any purpose, even commercially. You must give appropriate credit, provide a link to the license, and indicate if changes were made." Copyright (c) CALIPHO group, SIB Swiss Institute of Bioinformatics. Read on 14 Nov 2026 at https://ftp.expasy.org/databases/cellosaurus/README
- PubMed Central's articlesEach article's own license. Its words show only under CC0, CC BY or public domain
- NLM's PMC Article DatasetsNLM's PMC Article Datasets on AWS, https://registry.opendata.aws/ncbi-pmc. Its terms: users "acknowledge NLM as the source of the data in a clear and conspicuous manner", do not use the PubMed Central wordmark or the PMC logo, do not "indicate or imply that NLM/NIH/HHS has endorsed" a product, and "only distribute data that are licensed for redistribution". Each article keeps its own license: https://pmc.ncbi.nlm.nih.gov/about/copyright/
- PubMedNLM's terms
Cellosaurus, SIB Swiss Institute of Bioinformatics, https://www.cellosaurus.org, CC BY 4.0. Its problem notes are given in its own words.
For software
Read this list from software.
Twenty rows a page, as JSON. No key.
GET https://conductscience.org/api/cell-lines/v1/CVCL_5546/papers